Australian clinical-stage immuno-oncology company Imugene (ASX:IMU) has announced that the US FDA has granted Fast Track Designation to its allogeneic CAR T-cell therapy, azer-cel, for the treatment of relapsed or refractory diffuse large B-cell lymphoma. …
Imugene's azer-cel granted FDA Fast Track Designation in blood cancer
March 19, 2025 Australian Biotech
Latest Video
New Stories
-
New partnership promotes buy local for homegrown innovation
May 8, 2025 - - Latest News -
New Zealand to change laws to promote medical conferences
May 8, 2025 - - Latest News -
Australia is about to get a new industry minister
May 8, 2025 - - Latest News -
Internal promotions for new generation of leaders at Astellas
May 7, 2025 - - Latest News -
New study reveals the far-reaching impact of ovarian cancer
May 7, 2025 - - Latest News -
Just the threat of tariffs has secured a quarter of a trillion in investment
May 7, 2025 - - Latest News -
Percheron Therapeutics launches bonus loyalty option offer
May 7, 2025 - - Australian Biotech